Printer Friendly

Novo Nordisk Canada unveils Fiasp in Canada for achieving optimal mealtime glucose control in diabetic patients.

M2 EQUITYBITES-March 28, 2017-Novo Nordisk Canada unveils Fiasp in Canada for achieving optimal mealtime glucose control in diabetic patients

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Healthcare company Novo Nordisk Canada Inc reported on Monday the launch of Fiasp (insulin aspart) in Canada as a new treatment option for achieving optimal mealtime glucose control in diabetic patients in the country.

The company said Fiasp (insulin aspart), a faster acting mealtime insulin, is now approved and recommended by Diabetes Canada to reduce the incidence and slow the progression of diabetes-related complications. Fiasp is an innovative formulation with two excipients: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring Amino Acid (L-Arginine) for stability.

According to the company, Fiasp is an innovative formulation of insulin aspart that more closely matches the natural physiological insulin response of a person without diabetes, after a meal, compared with NovoRapid (conventional insulin aspart).

In addition, Fiasp has the option of a flexible dosing regimen (up to two minutes before a meal and up to 20 minutes after starting a meal), without compromising overall glycemic control or safety. Fiasp is absorbed faster than NovoRapid (conventional insulin aspart), appearing twice as fast in the bloodstream after injection.

Additionally, the efficacy and safety profile of Fiasp was investigated in the company's phase 3a onset clinical trial programme consisting of four trials, encompassing more than 2,100 people with type 1 and type 2 diabetes.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:1CANA
Date:Mar 28, 2017
Words:251
Previous Article:AstraZeneca gains China approval for lung cancer drug Tagrisso.
Next Article:Athene Holding launches secondary offering of 25,000,000 common shares.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters